Recon: Teva, Allergan reach $161.5M opioid settlement with W. Virginia; Pfizer pledges to sell drugs at no profit in low-income countries

• Teva, Allergan reach $161.5 million opioid settlement with West Virginia (Reuters)
• CVS Will Stop Filling Controlled-Substance Prescriptions for Cerebral, Done (WSJ)
• 'Hands may be tied': FDA slaps Verrica with 3rd CRL due to problems with contract manufacturer (Endpoints)
• GSK 'schemed' FDA's drug-device approval pathway to deflect asthma inhaler generics, lawsuit claims (Fierce)
• Whistleblower report on baby formula didn’t reach top FDA food safety official (Washington Post)

• Pfizer to sell all its patented drugs at nonprofit price in low-income countries (Reuters) (STAT)
• G20 pandemic fund ploughs ahead amid fears world not ready for future threats (Reuters)
• WHO member states agree to fix 'rotten' funding model (Reuters)
• French health body backs new COVID vaccine booster campaign for this autumn (Reuters)
• Bavarian Nordic raises sales guidance after monkeypox vaccine order (Reuters)
• AstraZeneca reviews diversity in trials to ensure drugs work for all (The Guardian)
• EU Tracking CTR Impact On Clinical Trials Environment (Pink Sheet)

• Explainer: What vaccines, treatments do we have to combat monkeypox? (Reuters)
• GSK avoids strike as UK workers accept pay negotiation (Endpoints)
• Pharma company continues its FDA lawsuit spree, this time after agency denies fast-track designation (Endpoints)
• Life sciences developer BioMed Realty buys San Francisco hotel for $75M — report (Endpoints)
• New kind of off-the-shelf cancer vaccine reduces metastasis in animal experiments (STAT)
• Cracks in the facade: Is pharma's pandemic ‘feel good factor’ waning? (Endpoints)
• Surprise US FDA Facility Inspections Resume In India (Pink Sheet)
• Closed-Loop Inspections? Strict COVID Zero Policy Delays FDA's China Field Trips (Pink Sheet)
• Are Trial Sponsors Treading On Investigators’ Toes In Decentralized Trials? (Pink Sheet)
• FDA starts clock on review of CSL, UniQure gene therapy (BioPharmaDive)
• Taking another shot at mRNA glory, CureVac inks oncology pact while keeping up with Covid work (Endpoints)
• While down 87% YOY, Evelo gets Flagship and others to infuse new capital for comeback hope (Endpoints)
• Antios' HBV collab axed after clinical hold, but biotech believes safety incident is not treatment-related (Endpoints)
• Former Principia team looks to shake up covalent small molecules again, this time at 'earthquake' scale (Endpoints)

• Verily advances smartwatch toward Parkinson’s clinical trial use after validating technology (MedtechDive)
• RapidAI speeds up pulmonary embolism diagnosis with FDA clearance for AI triage tool (Fierce)
• Multiomics startup Pleno nabs $15M for a telecom-based approach to analyzing DNA, RNA (Fierce)

• Moderna seeks to dismiss Alnylam suit over Covid-19 vaccine component, claiming wrong venue (Endpoints)
• Bristol Myers Squibb sues Novartis for royalties surrounding the use of transgenic mice (Endpoints)
• Mylan Hit With Infringement Suit Over MS Generic Drug (Law360)